Expressing support for the designation of May 15, 2025, as "Prader-Willi Syndrome Awareness Day" to raise awareness of and promote research on the disorder.
- Bill Number
- H.Res. 253
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-25: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-07-11T18:06:13Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 253) expresses congressional support for designating May 15, 2025, as "Prader-Willi Syndrome Awareness Day." Its main goal is to increase public awareness of Prader-Willi syndrome (PWS), a rare genetic disorder, and to encourage research into its causes, treatments, and potential cures.
Key Provisions
The resolution includes detailed background information (preamble "Whereas" clauses) on PWS and ends with a formal statement of support. Key elements include:
- Description of PWS: It affects about 1 in 15,000 births, impacting 10,000–20,000 people in the U.S. equally across genders, races, and ethnicities. Caused by issues on chromosome 15, it leads to insatiable hunger, severe obesity (a leading cause of death), low muscle tone, intellectual delays, emotional control issues, and other health problems like heart disease, diabetes, and hormone imbalances.
- Challenges and Needs: Highlights difficulties in diagnosis, limited treatments, high morbidity and mortality rates, and the lack of a cure. Early diagnosis and interventions like human growth hormone can improve quality of life, but many symptoms remain untreated.
- Role of Advocacy: Recognizes the Prader-Willi Syndrome Association (founded in 1975) for providing support, education, research networks, and advocacy to families and professionals.
- Research Benefits: Emphasizes that PWS research could advance understanding of broader issues like childhood obesity and mental health.
- Congressional Actions (Resolved section):
- Supports the Awareness Day designation.
- Applauds advocates, organizations, families, researchers, and health professionals for their efforts.
- Stresses the importance of public education, early diagnosis, research advancement, new treatments and cures, and streamlined regulatory paths for rare disease drugs.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no changes to existing laws or statutes. It serves as a symbolic gesture rather than enforceable legislation.
Potential Impacts
- On Citizens: May heighten public awareness of PWS, helping families access earlier diagnosis, support services, and treatments. It could reduce stigma and improve quality of life for the 10,000–20,000 affected individuals and their families by promoting education and hope.
- On Government Agencies: Encourages federal support for research (e.g., through agencies like the National Institutes of Health), but imposes no mandates or funding requirements.
- On International Relations: Minimal impact, though it acknowledges the association's international network, potentially fostering global collaboration on rare disease research.
- Overall, it could indirectly boost research funding and policy focus on rare genetic disorders without direct legal effects.
Main Stakeholders Affected
- Individuals with PWS and Families: Primary beneficiaries through increased visibility and access to resources.
- Prader-Willi Syndrome Association and Advocacy Groups: Recognized for their work, potentially gaining more support and influence.
- Researchers and Health Professionals: Encouraged to advance studies, treatments, and diagnostics for PWS and related conditions.
- General Public: Benefits from broader awareness of genetic disorders, obesity, and mental health issues.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no force of law and requires only House approval (no Senate or presidential involvement). It highlights regulatory pathways for rare disease drugs, which could influence future FDA policies without binding them.
- Constitutional: Aligns with Congress's role in promoting public welfare and health education under its general powers; no constitutional concerns.
- Political: Demonstrates bipartisan support (introduced by Mr. Tonko and Ms. Salazar) for rare disease advocacy, signaling congressional priority on underfunded health issues. It could build momentum for future binding legislation on genetic research or rare disease funding, emphasizing normalization and lifelong support for affected individuals.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Rep. Salazar, Maria Elvira [R-FL-27]
Recent Actions
- 2025-03-25: Referred to the House Committee on Energy and Commerce.
- 2025-03-25: Submitted in House
- 2025-03-25: Submitted in House
Bill Versions
- Expressing support for the designation of May 15, 2025, as "Prader-Willi Syndrome Awareness Day" to raise awareness of and promote research on the disorder. — issued 2025-03-25 — PDF (5 pages)